Radical surgical procedure improves survival time in patients with recurrent ovarian cancer.
about
Cancer of the endometrium: current aspects of diagnostics and treatmentCytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancerRole of cytoreductive surgery in recurrent ovarian cancer.Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics.Cytoreductive Surgery in Ovarian Cancer: Why, When, and How?Current management of epithelial ovarian carcinoma: a review.Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort.Survival Impact of Secondary Cytoreductive Surgery for Recurrent Ovarian Cancer in an Asian PopulationThe role of secondary surgery in recurrent ovarian cancer.Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma.Safety and efficacy of video laparoscopic surgical debulking of recurrent ovarian, fallopian tube, and primary peritoneal cancers.Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection.Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.Splenectomy and surgical cytoreduction in epithelial ovarian cancer: a review.Secondary Surgery Versus Chemotherapy for Recurrent Ovarian Cancer.Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer.Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.Secondary Cytoreduction in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Institution Experience.Comparison of secondary cytoreductive surgery plus chemotherapy with chemotherapy alone for recurrent epithelial ovarian, tubal, or peritoneal carcinoma: A propensity score-matched analysis of 112 consecutive patients.Secondary cytoreductive surgery outcomes of selected patients with paclitaxel/platinum sensitive recurrent epithelial ovarian cancer.Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer
P2860
Q24797130-C1519683-1672-4F85-8725-446AD8FF51B0Q24800974-0015AE94-2481-422A-A721-6ED66869BFCEQ30378801-B2C12077-F53D-4709-93BD-CFB37AE71837Q30444706-A96C6A14-CD60-456F-8495-58F08DEAAA57Q30866485-0487FF7D-C51F-4323-9207-40EAEA4B2682Q33959810-5CE927AD-BFB1-42CC-82D0-FB2EEB514390Q35262997-E4D0281B-AA53-4C4C-8CAE-590DE0F05C1EQ36076868-260A32D8-8172-421A-82EE-BCFD27858756Q36167425-76078B72-546F-4A09-8CF2-23E96F88DC7DQ36407477-65F1C32A-FC6A-49C5-A88E-DB55BEABA95DQ36573447-DA38017D-AC87-452D-A54A-DD738AF63E34Q36616507-6D52E075-21CF-4713-8E04-41C94A73E654Q36619276-AA655BD6-2A9F-4937-856E-76F9C8B0CDEBQ37786359-E2D6833D-F62F-4C46-99A8-558242149D24Q39621533-D8CF047E-F1F0-4BEF-B01E-40C34BB713C1Q39848961-156BC320-452A-4031-8474-AAD31426320CQ40270631-DF8EEC6B-2EDF-4B1D-8DE6-BAF534E920C7Q41174367-CC46E77C-706E-4844-AF9A-75E02AF0E414Q42360773-BAC0220C-8E71-4975-AA5F-AF76BE2D6E8EQ43695138-34A718DA-C713-428C-9775-AAA1DECD9675Q57940964-B0D80D49-FD49-409D-A373-0C77A16AA1F3
P2860
Radical surgical procedure improves survival time in patients with recurrent ovarian cancer.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh-hant
name
Radical surgical procedure imp ...... with recurrent ovarian cancer.
@en
Radical surgical procedure imp ...... with recurrent ovarian cancer.
@nl
type
label
Radical surgical procedure imp ...... with recurrent ovarian cancer.
@en
Radical surgical procedure imp ...... with recurrent ovarian cancer.
@nl
prefLabel
Radical surgical procedure imp ...... with recurrent ovarian cancer.
@en
Radical surgical procedure imp ...... with recurrent ovarian cancer.
@nl
P2093
P1433
P1476
Radical surgical procedure imp ...... with recurrent ovarian cancer.
@en
P2093
Hölscher M
Siewert JR
von Hugo R
P304
P356
10.1002/1097-0142(19921015)70:8<2129::AID-CNCR2820700820>3.0.CO;2-U
P407
P577
1992-10-01T00:00:00Z